Zhu Jianfei, Wang Wuping, Xu Shuonan, Jia Chenghui, Zhang Qingqing, Xia Yanmin, Wang Wenchen, Wen Miaomiao, Wang Xuejiao, Wang Hongtao, Zhang Zhipei, Cai Ling, Zhang Lanjun, Jiang Tao
Department of Thoracic Surgery, Tangdu Hospital, Air Force Medical University (Fourth Military Medical University), Xi'an, China.
Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
Front Oncol. 2020 Oct 19;10:563700. doi: 10.3389/fonc.2020.563700. eCollection 2020.
Grade prognostic assessment (GPA) is widely used to evaluate the prognosis of non-small cell lung cancer (NSCLC) patients with brain metastases (BMs). This study aimed to investigate whether lymph node status (LNS) could be included as one of the GPA variables for NSCLC with BMs.
Overall, 586 patients with NSCLC and BMs were retrospectively analyzed. Overall survival stratified by LNS was analyzed using the Kaplan-Meier method. Multivariate analysis was also performed to identify independent prognostic factors using the Cox proportional hazards progression model. In the updated GPA index, prognostic factors and criteria of GPA score were weighted by effect magnitude relative risk (RR) and statistical significance.
In NSCLC patients with BMs, those with lymph node involvement had worse overall survival (mOS, 13.4 months vs. 25.9 months, P <0.001) than those without lymph node involvement. Multivariate analysis showed that LNS might be an independent prognostic factor (RR: 1.702, CI: 1.340-2.162, P <0.001). Finally, five prognostic factors including LNS, the age of the patient, Karnofsky performance status (KPS), the number of BMs, and extracranial metastases were enrolled in our novel GPA index. With the updated GPA index involving the N stage, survival analysis was also performed. Prognostic results were significantly different among these four subgroups (Class A vs. Class B, P=0.047; Class B vs. Class C, P<0.001; Class C vs. Class D, P=0.007).
These results indicate that LNS might be an indispensable prognostic factor in NSCLC with BM. The novel GPA model involving the N stage could provide more reliable evidence to estimate the survival of NSCLC patients with BMs.
分级预后评估(GPA)广泛用于评估非小细胞肺癌(NSCLC)脑转移(BM)患者的预后。本研究旨在探讨淋巴结状态(LNS)是否可纳入NSCLC伴BM的GPA变量之一。
总体而言,对586例NSCLC伴BM患者进行回顾性分析。采用Kaplan-Meier法分析按LNS分层的总生存期。还使用Cox比例风险进展模型进行多变量分析以确定独立预后因素。在更新的GPA指数中,GPA评分的预后因素和标准通过效应量相对风险(RR)和统计学意义进行加权。
在NSCLC伴BM患者中,有淋巴结受累的患者总生存期(mOS,13.4个月对25.9个月,P<0.001)比无淋巴结受累的患者差。多变量分析表明LNS可能是一个独立预后因素(RR:1.702,CI:1.340 - 2.162,P<0.001)。最后,包括LNS、患者年龄、卡诺夫斯基功能状态(KPS)、BM数量和颅外转移在内的五个预后因素被纳入我们的新型GPA指数。对于纳入N分期的更新GPA指数,也进行了生存分析。这四个亚组的预后结果有显著差异(A类对B类,P = 0.047;B类对C类,P<0.001;C类对D类,P = 0.007)。
这些结果表明LNS可能是NSCLC伴BM中不可或缺的预后因素。纳入N分期的新型GPA模型可为评估NSCLC伴BM患者的生存提供更可靠的证据。